


Active Filter(s):
Details:
High dose IDCT (Allogeneic Discogenic Progenitor Cell Therapy) also produced clinically meaningful, statistically significant improvements in function and quality of life by 12 weeks following intradiscal injection with durability sustained at the one-year interim readout.
Lead Product(s): Allogeneic Discogenic Progenitor Cell Therapy
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: IDCT
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2022
Details:
This prospective, randomized, double-blinded, sham-controlled, multicenter clinical study is designed to evaluate the safety and preliminary efficacy of IDCT in patients with symptomatic, single-level, mild to moderate lumbar disc degeneration.
Lead Product(s): Rebonuputemcel
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: IDCT
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2021